Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  DANG THU A
 2. Date of Event Requiring Statement (Month/Day/Year)
06/20/2006		 3. Issuer Name and Ticker or Trading Symbol
CYTOGEN CORP [CYTO]
(Last)
(First)
(Middle)
C/O CYTOGEN CORP, 650 COLLEGE RD E		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) __X__ Other (specify below)
Principal Financial Officer / Principal Accounting Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

PRINCETON, NJ 08540		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock (1) 6,000
D
 
Common Stock (1) 5,400
D
 
Common Stock 1,209
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase Common Stock 12/18/1997 12/18/2007 Common Stock 720 $ 20.625 D  
Options to purchase Coomon Stock 01/20/1998 11/26/2006 Common Stock 440 $ 19.53 D  
Options to purchase Common Stock 12/31/1999 12/31/2009 Common Stock 151 $ 26.72 D  
Options to purchase Common Stock 12/31/1999 12/31/2009 Common Stock 775 $ 26.72 D  
Options to purcchase Common Stock 12/19/2000 12/19/2010 Common Stock 1,000 $ 29.065 D  
Options to purchase Common Stock 12/18/2001 12/18/2011 Common Stock 865 $ 34.9 D  
Options to purchase Common Stock 12/17/2002 12/17/2012 Common Stock 1,600 $ 3.54 D  
Options to purchase Common Stock 02/13/2003 02/13/2013 Common Stock 1,000 $ 2.865 D  
Options to purchase Common Stock 10/21/2003 10/21/2013 Common Stock 6,856 $ 11.48 D  
Options to purchase Common Stock 06/15/2004 06/15/2014 Common Stock 5,000 $ 11.5 D  
Options to purchase Common Stock 06/14/2005 06/14/2015 Common Stock 9,000 $ 5.15 D  
Options to purchase Common Stock 04/04/2006 04/04/2016 Common Stock 7,500 $ 3.575 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
DANG THU A
C/O CYTOGEN CORP
650 COLLEGE RD E
PRINCETON, NJ 08540		       Principal Financial Officer Principal Accounting Officer

Signatures

/s/ Thu Dang 06/29/2006
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Such shares of restricted common stock were issued as a long-term incentive pursuant to the terms of the Company's 2004 Stock Incentive Plan and vest over a period of ten years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.